Drugs / adenovirus-p53 transduced dendritic cell (DC) vaccine
adenovirus-p53 transduced dendritic cell (DC) vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01042535 | Dec 2009 → Dec 2014 | male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adenovirus-p53 transduced dendritic cell (DC) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01042535 ↗ |
| Modality | Vaccine | “Ad.p53 DC vaccine (adenovirus-p53 transduced dendritic cell vaccine)” NCT01042535 ↗ |